Immune Design Halts Phase III Trial of Lead Candidate CMB305, Ramps Up G100 Development

Immunotherapy developer Immune Design said it will halt a Phase III trial for its lead pipeline candidate, the cancer vaccine CMB305, following disappointing Phase II results in synovial sarcoma, and will instead accelerate and expand development of its next-furthest along candidate, the intratumoral TLR4 agonist G100.Immune Design said it will “deprioritize” development of CMB305, a prime-boost cancer vaccine designed to target tumors that express the cellular protein NY-ESO-1, whic